Cell Stress & Chaperones, Vol. 29, No. 5 (2024), pp. 666-680 (15 pages) Doxorubicin (DOX) is the most commonly used anthracycline anticancer agent, while its clinical utility is limited by harmful ...
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial Purpose: This ...
De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.
Race Oncology has identified major new opportunities in two new cancer indications for its RC220 therapy after identifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback